-
-
-
-
-
-
-
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
-
-
-
-
-
-
-
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
-
1,222,851 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

